Overview

Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2025-12-30

Target enrollment:

Participant gender:

Summary

The goal of this open, single-arm practical, phase II, clinical study is to evaluate the efficacy and safety of the mitoxantrone hydrochloride liposome injection-containing regimens in bridging therapies of CD19 CAR-T cells. The main question it aims to answer is: • the efficacy of the mitoxantrone hydrochloride liposome injection-containing combination regimens in bridging therapies of CD19 CAR-T cells. Participants will receive combination bridging regimens including mitoxantrone hydrochloride liposomal injection and CAR-T cell therapy to see if the combination regimens have a positive effect on the efficacy of bridging therapies.

Phase:

PHASE2

Details

Lead Sponsor:

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Collaborator:

CSPC Pharmaceutical Group Limited